Phio Pharmaceuticals Corp.
PHIO
$1.26
$0.097.69%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/16/2026
-
Newsfile Corp. - News Releases
3/13/2026
-
Globe Newswire
3/10/2026
-
Globe Newswire
3/10/2026
-
Globe Newswire
3/10/2026
-
Globe Newswire
3/10/2026
-
Newsfile Corp. - News Releases
3/5/2026
-
Newsfile Corp. - News Releases
3/5/2026
-
Newsfile Corp. - News Releases
2/19/2026
-
Newsfile Corp. - News Releases
2/10/2026
-
Ticker Report
2/10/2026
-
TipRanks Financial Blog
2/10/2026
-
Newsfile Corp. - News Releases
2/2/2026
-
Ticker Report
1/26/2026
-
Newsfile Corp. - News Releases
1/23/2026
-
ACCESS Newswire
1/20/2026
-
Newsfile Corp. - News Releases
1/15/2026
-
Newsfile Corp. - News Releases
1/2/2026
-
GuruFocus
12/31/2025
-
Ticker Report
12/23/2025
-
TipRanks Financial Blog
12/23/2025
-
Newsfile Corp. - News Releases
12/16/2025
-
Zolmax
11/25/2025
-
Newsfile Corp. - News Releases
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, March 5, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
610 947 0251
Address
411 Swedeland Road
King Of Prussia, PA 19406
King Of Prussia, PA 19406
Country
Year Founded
Business Description
Sector
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound...
more